Enzolytics Acknowledges World AIDS Day and Highlights the Firm’s Give attention to Producing Efficient Therapies for Treating HIV

COLLEGE STATION, TX / ACCESSWIRE / December 1, 2022 / Enzolytics, Inc. (OTC PINK:ENZC) (https://enzolytics.com/).

World AIDS Day has been acknowledged on at the present time since 1988. It is a vital day for the world to mirror on those that have been misplaced within the HIV pandemic and recommit to the problem vital to deal with this lethal illness.

However why has the world failed to overcome HIV?

Regardless that there are remedies for these with HIV – antiretroviral medicine (ARVs) -, the remedies don’t treatment and require lifelong use – which over a lifetime trigger extreme uncomfortable side effects together with bone loss, coronary heart illness, diabetes, lactic acidosis, kidney, liver, or pancreas harm, amongst others.

Moreover, ARV remedies are extraordinarily costly. New ARV medicine akin to Biktarvy by Gilead can prices as much as $75K per 12 months. Cabenuva by VIIV Healthcare prices $48K a 12 months. Consequently, of the 38.4 Million individuals on this planet who’ve HIV, solely 69% have entry to any accessible remedy, leaving 31% with no remedy. Of kids on this planet with HIV, solely 50% have entry to remedy, leaving 50% with no remedy.

Throughout the pandemic, over 40 Million have died from the virus. In 2021, 860,000 died from HIV, over 2,000 every day. Every day in 2021, roughly 850 youngsters grew to become contaminated with HIV and roughly 301 youngsters died from AIDS-related causes.

In 2021, 301 youngsters died every day from HIV. Greater than the variety of youngsters who succumb to most cancers.

Makes an attempt to provide monoclonal antibodies to efficiently deal with HIV haven’t succeeded. The anti-HIV monoclonal antibodies VRC01 and VRC02, produced by the NIH together with Vaccine Analysis Heart, failed – as a consequence of virus mutation – particularly “virus escape”. https://www.jci.org/articles/view/134395. Many different makes an attempt have additionally not been profitable in offering efficient remedy at an affordable price.

On this World AIDS Day, Enzolytics needs to name consideration to the continued want for simpler, and inexpensive remedies for HIV, together with profitable remedies for the rising variety of people dwelling longer with HIV. As a result of virtually ½ of these with HIV at the moment are 50 or older and roughly 1 in 6 new diagnoses of HIV happen on this age group, individuals growing old with HIV can face treatment-related challenges, akin to drug interactions between HIV medicines and medicines used for different circumstances. As a result of older people are extra doubtless to not be identified with HIV, a delayed prognosis means remedy can also be delayed, leading to HIV probably inflicting extra harm to the immune system. Moreover, information counsel that untreated HIV is ensuing within the improvement of SARS-CoV-2 variants. On this regard, the Firm’s know-how stays targeted on each HIV and SARS-CoV-2.

The Firm’s applied sciences give attention to a definitive remedy for treating HIV in comparison with the present remedy utilizing ARVs. Particularly, the Firm is advancing two platforms, one being a clinically examined, patented, antiviral therapeutic, generally known as ITV-1, that has proven important effectiveness in treating sufferers with HIV/AIDS. This therapeutic is complementary to the Firm’s improvement of absolutely human monoclonal antibodies that focus on and neutralize the virus. Specialists within the area have constantly acknowledged {that a} treatment for HIV would require the administration of “a number of, broadly neutralizing monoclonal antibodies.” Simply as a number of anti-CoronaVirus monoclonal antibodies at the moment are widely known as efficient in treating these with COVID-19, the identical shall be true for anti-HIV monoclonal antibodies. However to achieve success, such antibodies should be “broadly neutralizing” – that’s, they need to goal conserved, immutable websites not rendered ineffective by mutant strains of the HIV virus. That is precisely the main target of the Firm’s know-how.


To boost its manufacturing of efficient anti-HIV monoclonal antibodies, the Firm has employed Synthetic Intelligence (A.I.), utilizing laptop evaluation to curate (analyze) the amino acid sequences of focused viruses to determine the conserved, immutable, and neutralizable goal websites (epitopes) on viruses. As soon as recognized, the Firm makes use of its proprietary know-how to provide absolutely human monoclonal antibodies that focus on these recognized immutable websites – thereby producing a therapeutic that doesn’t fail as a consequence of virus mutations – generally known as virus escape. Moreover, these recognized goal websites could also be used to develop simpler vaccines – a vaccine improvement methodology considerably totally different than mRNA vaccine manufacturing.

Utilizing Synthetic Intelligence, Enzolytics has recognized immutable conserved epitopes for quite a few viruses and is concentrated on producing monoclonal antibodies concentrating on these websites. The Firm has absolutely analyzed over 87,000 HIV isolates utilizing A.I. figuring out 8 conserved epitopes and over 2 Million COVID-19 isolates to determine 19 conserved epitopes. The Firm is within the course of of manufacturing antibodies concentrating on these conserved websites. These conserved epitope websites on the HIV and CoronaVirus are claimed within the Firm’s now pending PCT patent functions.

The far-reaching nature of the Firm’s A.I. evaluation is seen by noting that along with curating isolates of HIV and COVID-19, the Firm has absolutely analyzing every of the next viruses and recognized the conserved epitopes on the viruses: HTLV-1, H10N3, Influenza A, and B, H1N1 influenza, Respiratory syncytial virus (RSV), Ebola, Small-Pox, Tetanus, Diphtheria, Rabies, Herpes zoster, Varicella zoster, Anthrax, Elephant endotheliotropic herpesviruses, Feline Leukemia Virus, Equine Infectious Anemia Virus, Feline Immunodeficiency virus, Small Ruminant Lentivirus, and Koala retrovirus. The Firm’s future efforts are manufacturing of monoclonal antibodies concentrating on these virus websites. PCT Patent Functions shall be filed overlaying these discoveries.

The Firm’s A.I. is critical for the next causes:

  1. The A.I. platform incorporates genomic surveillance and monitoring of virus epidemiology. The Enzolytics AI group is engaged on a complete Synthetic Intelligence protocol to investigate present viruses and any new virus instantly upon its emergence globally.
  2. Enzolytics additionally makes use of A.I. to evaluate the results of Genetics, Diet, and the Human Microbiome on infectious illnesses, psychological well being issues, and continual medical illnesses. The aim of this focus is to:
  3. Construct prediction fashions for infectious illnesses, psychological well being issues, and continual medical illnesses.
  4. Determine biomarkers for infectious illnesses, psychological well being issues, and continual medical illnesses.
  5. Determine novel targets and clear intervention methods for infectious illnesses, psychological well being issues, and continual medical illnesses.

That is a part of Enzolytics’ strategic effort to increase to the personalised drugs market and improve its Mental Property portfolio. The Firm’s Chief Working Officer, Dr. Gaurav Chandra, has described the position of Synthetic Intelligence in understanding the microbiome, resulting in biomarkers, modern diagnostic instruments, and novel remedy methods in illnesses in an article “Demystifying the Human Microbiome utilizing Synthetic Intelligence” printed within the Yuan (https://www.the-yuan.com/177/Demystifying-the-Human-Microbiome-Utilizing-AI.html).


Addressing the HIV pandemic, the Firm has two expectedly complementary therapeutics directed to the efficient remedy of HIV. One therapeutic, ITV-1, a patented antiviral peptide that has been clinically examined, is a suspension of Inactivated Pepsin Fragment (IPF), a purified extract of porcine pepsin. This therapeutic has been proven to strengthen the immune system and has been examined in HIV sufferers in scientific trials with important useful outcomes. [https://enzolytics.com/proprietary-therapeutics/]. At the moment, the Firm is advancing this anti-HIV therapeutic for approval underneath the European Medicines Company (EMA) to be used in European Union nations.

The Firm additionally is concentrated on deploying this examined therapeutic in African nations, the place the HIV pandemic is extreme. Upon completion of ultimate Toxicity Research of ITV-1, the Firm plans to have the ability to make ITV-1 accessible within the nations in Africa, together with Rwanda, the Democratic Republic of Congo, Angola, Kenya, and South Africa. The Firm sees this as important for people in Africa recognizing that out of the 38.4 Million HIV-positive individuals worldwide, 69% dwell in sub-Saharan Africa. There are roughly 23.8 Million contaminated individuals in all of Africa. 40% of these contaminated with HIV in Africa do not need any entry to any remedy for the virus. As well as, 91% of the world’s HIV-positive youngsters dwell in Africa.

The second therapeutic for treating HIV, the Firm’s anti-HIV monoclonal antibodies, are additionally in improvement. The Firm’s major anti-HIV antibody has been produced from the guardian antibody within the recombinant kind (a kind vital for affected person remedy) by Samsung Biologics. Samsung Biologics will present end-to-end CDMO companies from cell line improvement, scientific drug substance, and drug product manufacturing companies to help IND filings for Anti-HIV Monoclonal Antibody Remedy for the remedy of HIV. The Firm notes that this anti-HIV mAb targets an immutable web site on the HIV virus that has existed unchanged over 30 years of research of the virus. Which means the goal is not going to mutate rendering the antibody ineffective.


Addressing the COVID-19 pandemic, the Firm is producing monoclonal antibodies concentrating on conserved websites on the SARS-CoV-2 virus recognized utilizing Synthetic Intelligence. The conserved focused conserved websites are present in all variants of concern – together with the COVID-19 Omicron variant. Thus, the monoclonal antibodies being produced by the Firm, because of the conserved nature of the focused epitopes, are anticipated to be efficient towards present and future variants of the COVID-19 virus.

The Firm is utilizing a number of processes to speed up the manufacturing of those monoclonal antibodies. As acknowledged by consultants within the area, quite a few monoclonal antibodies are wanted for efficient remedy. Through the use of accelerated know-how programs in collaboration with Abveris, a division of Twist Bioscience Company, desired antibodies could also be produced in shorter time frames. Abveris applies superior immunization strategies mixed with B cell screening and hybridoma-based antibody discovery applied sciences to offer complete gene-to-antibody discovery companies. As well as, the Firm has a robust working relationship with Samsung Biologics, which offers end-to-end CDMO companies from cell line improvement, scientific drug substance, and drug product manufacturing companies to help IND filings for produced antibodies.


  1. The Firm is now producing its “Enzolytics IPF Immune™,” a liquid dietary complement that gives help for the physique’s immune system. The energetic parts within the complement have been registered with the FDA to be used within the U.S. underneath NDI Reg. No. 1083. The Firm’s product is produced and offered pursuant to its license underneath U.S. Patent No. 8,309,072 (the ‘072 Patent). This ‘072 Patent, entitled “Irreversibly-Inactivated Pepsinogen Fragments for Modulating Immune Operate,” covers the usage of Irreversibly Inactivated Pepsin Fragments (IPF). The first IPF ingredient is a fancy platform that gives help for the immune system. The U.S. vitamin and complement trade at the moment totals $35.6 Billion in 2022 whereas the worldwide sector is value $151.9 Billion. The Firm expects the product to be very properly acquired by shoppers.

CEO Charles Cotropia mentioned, “On this previous 12 months, we have now made nice progress in advancing a number of platforms for offering a number of therapeutics for the remedy of many important human circumstances. Whereas we’re proud of our latest progress, we all know we shall be profitable going ahead given the big selection of our applied sciences and the a number of platforms we have now developed. These platforms will make doable our manufacturing of therapeutics overlaying an in depth vary of illnesses for which therapies are desperately wanted.”

About Enzolytics, Inc.

Enzolytics, Inc. is a drug improvement firm dedicated to commercializing its proprietary proteins and monoclonal antibodies for the remedy of debilitating infectious illnesses. The Firm is advancing a number of therapeutics concentrating on quite a few infectious illnesses. One patented and clinically examined compound, ITV-1 (Immune Therapeutic Vaccine-1), is a suspension of Inactivated Pepsin Fraction (IPF), lined by U.S. Patent Nos. 8,066,982 and seven,479,538. Research have proven it to be efficient in treating HIV/AIDS. IPF is the energetic element of ITV-1 and is a purified extract of porcine pepsin. ITV-1 has additionally been proven to modulate the immune system.

The Firm can also be implementing its proprietary know-how to provide absolutely human monoclonal antibodies (mAbs) towards infectious illnesses, together with HIV, SARS CoV-2, rabies, influenza A, influenza B, tetanus, and diphtheria. Its proprietary methodology, lined in a number of PCT Patent Functions for producing absolutely human monoclonal antibodies, is at the moment employed to provide monoclonal antibody therapeutics for quite a few infectious illnesses, together with the Coronavirus (SARS-CoV-2) and HTLV-1.

Protected Harbor Assertion: This information launch comprises forward-looking statements that contain dangers and uncertainties related to monetary projections, budgets, milestone timelines, scientific improvement, regulatory approvals, and different dangers described by Enzolytics, Inc. on occasion in its periodic studies filed with the SEC. ITV-1 isn’t permitted by the U.S. Meals and Drug Administration or by any comparable regulatory businesses elsewhere on this planet.

Whereas Enzolytics, Inc. believes that the forward-looking statements and underlying assumptions contained therein are affordable, any of the assumptions might be inaccurate, together with, however not restricted to, the flexibility of Enzolytics to ascertain the efficacy of its therapeutics within the remedy of any illness or well being situation, the event of research and techniques resulting in commercialization of its therapeutics in the USA, the acquiring of funding required to hold out the event plan, the completion of research and checks on time or in any respect, and the profitable consequence of such research or checks. Subsequently, there might be no assurance that the forward-looking statements included on this launch will show to be correct.

Such forward-looking statements are primarily based on present expectations. They contain inherent dangers and uncertainties, together with components that would delay, divert or change any of the statements made, and trigger precise outcomes and outcomes to vary materially from present expectations. No forward-looking assertion might be assured. These forward-looking statements are made as of the date of this press launch. The Firm expressly disclaims any intention or obligation to replace the forward-looking statements or replace the the reason why precise outcomes may differ from these projected within the forward-looking statements.

Firm Contact:

Enzolytics, Inc.

Texas A&M College

Institute for Preclinical Research

School Station, TX 77843-44


SOURCE: Enzolytics, Inc.

View supply model on accesswire.com:



Leave a Reply

Your email address will not be published. Required fields are marked *